Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses

Joseph H. Cioffi, Derek J. Estes, Vaia Florou, Bach Ardalan

Research output: Contribution to journalArticle

Abstract

A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose. After careful considerations, the decision was made to attempt capecitabine retrial at a further suboptimal dose with combination chemotherapy where she no longer experienced cardiac events. As a result, the liver tumour shrank and rectal mass stabilised, tumour markers dropped and she underwent surgical resection of both masses. Later there was local recurrence of disease near the previous liver tumour, so the suboptimal capecitabine therapy was restarted without complaint. The patient became a candidate for a NanoKnife procedure, offering a potentially curative therapy. This case report summarises a novel treatment strategy for those patients with advanced colorectal cancer who experience cardiotoxic reactions to fluoropyrimidines, the active agent of gold standard treatment.

Original languageEnglish (US)
Article number220952
JournalBMJ Case Reports
Volume2017
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Fluorouracil
Colorectal Neoplasms
Liver
Therapeutics
Prodrugs
Rectal Neoplasms
Tumor Biomarkers
Combination Drug Therapy
Capecitabine
Neoplasm Metastasis
Recurrence
Neoplasms

Keywords

  • cancer intervention
  • chemotherapy
  • colon cancer
  • unwanted effects / adverse reactions

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. / Cioffi, Joseph H.; Estes, Derek J.; Florou, Vaia; Ardalan, Bach.

In: BMJ Case Reports, Vol. 2017, 220952, 01.01.2017.

Research output: Contribution to journalArticle

@article{05faeb9fe5a7489e899517b152f7ad3f,
title = "Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses",
abstract = "A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose. After careful considerations, the decision was made to attempt capecitabine retrial at a further suboptimal dose with combination chemotherapy where she no longer experienced cardiac events. As a result, the liver tumour shrank and rectal mass stabilised, tumour markers dropped and she underwent surgical resection of both masses. Later there was local recurrence of disease near the previous liver tumour, so the suboptimal capecitabine therapy was restarted without complaint. The patient became a candidate for a NanoKnife procedure, offering a potentially curative therapy. This case report summarises a novel treatment strategy for those patients with advanced colorectal cancer who experience cardiotoxic reactions to fluoropyrimidines, the active agent of gold standard treatment.",
keywords = "cancer intervention, chemotherapy, colon cancer, unwanted effects / adverse reactions",
author = "Cioffi, {Joseph H.} and Estes, {Derek J.} and Vaia Florou and Bach Ardalan",
year = "2017",
month = "1",
day = "1",
doi = "10.1136/bcr-2017-220952",
language = "English (US)",
volume = "2017",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses

AU - Cioffi, Joseph H.

AU - Estes, Derek J.

AU - Florou, Vaia

AU - Ardalan, Bach

PY - 2017/1/1

Y1 - 2017/1/1

N2 - A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose. After careful considerations, the decision was made to attempt capecitabine retrial at a further suboptimal dose with combination chemotherapy where she no longer experienced cardiac events. As a result, the liver tumour shrank and rectal mass stabilised, tumour markers dropped and she underwent surgical resection of both masses. Later there was local recurrence of disease near the previous liver tumour, so the suboptimal capecitabine therapy was restarted without complaint. The patient became a candidate for a NanoKnife procedure, offering a potentially curative therapy. This case report summarises a novel treatment strategy for those patients with advanced colorectal cancer who experience cardiotoxic reactions to fluoropyrimidines, the active agent of gold standard treatment.

AB - A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose. After careful considerations, the decision was made to attempt capecitabine retrial at a further suboptimal dose with combination chemotherapy where she no longer experienced cardiac events. As a result, the liver tumour shrank and rectal mass stabilised, tumour markers dropped and she underwent surgical resection of both masses. Later there was local recurrence of disease near the previous liver tumour, so the suboptimal capecitabine therapy was restarted without complaint. The patient became a candidate for a NanoKnife procedure, offering a potentially curative therapy. This case report summarises a novel treatment strategy for those patients with advanced colorectal cancer who experience cardiotoxic reactions to fluoropyrimidines, the active agent of gold standard treatment.

KW - cancer intervention

KW - chemotherapy

KW - colon cancer

KW - unwanted effects / adverse reactions

UR - http://www.scopus.com/inward/record.url?scp=85036536232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036536232&partnerID=8YFLogxK

U2 - 10.1136/bcr-2017-220952

DO - 10.1136/bcr-2017-220952

M3 - Article

C2 - 29183892

AN - SCOPUS:85036536232

VL - 2017

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - 220952

ER -